Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a maintenance update to the page. There are no visible content or functionality changes indicated by the provided data.SummaryDifference0.0%

- Check23 days agoChange DetectedThe revision label on the page was updated from v3.6.0 to v3.6.2, signaling a recent update to the study details page.SummaryDifference0.0%

- Check37 days agoChange DetectedNew guidance sections were added to help users read the study record, answer common questions, and learn how to join, and the Intervention/Treatment label was updated. The recruitment status now shows 'No longer looking for participants', indicating enrollment has ended.SummaryDifference0.4%

- Check45 days agoChange DetectedRevision: v3.5.5 is now shown, replacing the previous v3.5.4. This indicates a minor update to the page content or structure without altering the underlying study information.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now displays a new revision tag 'Revision: v3.5.4', replacing the previous 'Revision: v3.5.3'. This reflects a minor version update to the page rather than any substantive changes to the study details.SummaryDifference0.1%

- Check88 days agoChange DetectedThe page’s displayed revision/version marker was incremented from v3.5.2 to v3.5.3, reflecting a site release/update rather than a change to the study information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.